All News

We are delighted to announce that Mark Chadwick, CEO at Physiomics Plc has been accepted to present at this year’s biopartnering and investment conference. Read more about the conference. ...

Dr Mark Chadwich has been accepted to present at the BIO-Europe Spring conference this year. Read more about the conference ...

Dr Mark Chadwick has been accepted to give a presentation during the second pre-clinical session at 2.10pm at EPIC this year. Read more about the conference ...

Physiomics is an Oxford-based systems biology company specialised in computational modelling of complex biological systems. Our models are based on sets of mathematical equations that simulate key biological processes, and are used by pharmaceutical companies to accelerate their internal drug discovery and development programs. We have an opportunity for a Biosimulation Scientist to join our technical team to work on projects related to drug development....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has completed the re-structuring of its Scientific Advisory Board (“SAB”). Read more...

Physiomics is delighted to announce the publication by Springer of the book ‘Cancer Systems Biology, Bioinformatics and Medicine’ in the Research and Clinical Applications series. Physiomics’ scientists have written the chapter 14 entitled “Systems biology approaches to cancer drug development.” “This teaching monograph on systems approaches to cancer research and clinical applications provides a unique synthesis, by world-class scientists and doctors, of laboratory, computational, and clinical...